The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

In a report released on January 14, Evan Seigerman from BMO Capital reiterated a Hold rating on Replimune Group, with a price target of $11.00. The company’s shares closed yesterday at $7.71.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...